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ABSTRACT 
The aim of this study was to evaluate if amniotic fluid (AF) mixed with artificial tears or soaked with a soft contact 
lens (SCL) as a treatment for severe dry eye disease (DED) would improve its signs or symptoms. In this 
retrospective pilot study 22 consecutive eyes of 11 patients with level 3 DED classified by DEWS 1 (Dry Eye 
WorkShop 1 2007), were included in the study between June 1 and September 30 in 2017. The study was conducted 
before DEWS II (Dry Eye WorkShop II 2017), which was published in October 2017. Therefore, DEWS II was not 
adopted for this study. Soft Contact Lens Acuvue Oasys of Plano with 8.8 base curve and 14 mm diameters by 
Johnson and Johnson were used to soak in FloGraft, which is an AF, for 30 minutes before placing in 12 eyes in 
Group 1. The contact lenses were placed in the left eye for 1 week. In Group 2, 10 eyes used 6 mL of artificial tears 
mixed with 0.25 mL of AF, which were applied to the eye four times a day for 1 week. No other eye medications 
were used. The eyes that were included had diffuse punctate staining and fast tear breaking times of <5 seconds 
with severe ocular symptoms (DEWS 1 level 3-4). Photos of fluorescein stain corneas before the treatment and 1 
week after the treatment were used to compare the distribution of punctate staining as the objective outcomes for 
signs. Several questions adopted from the Ocular Surface disease Index (OSDI) about subjective symptoms before 
and after the treatment were asked, and documented on the chart. Improvement either in symptoms or signs or 
both of DED after 1 week at follow-up examination was recorded. Group 1, with SCL 46% had improvement after 1 
week and Group 2, with artificial tears 50% had improvement after 1 week. Improvement means either symptom 
relief or comparatively decreased distribution of punctate staining on the cornea or both. No cases had 
inflammation, infection, irritation or blurred vision. We concluded that FloGraft as an AF can safely improve the 
symptoms or the signs of severe DED either as a mix with artificial tears or soaked with SCL by about 50% in this 
case series without evidence of irritation, inflammation or blurred vision in the short term. 
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INTRODUCTION
The incidence of dry eyes in the population has been 
reported to range from 7.4% to 33.7% with increased 
incidence in females and the elderly [1]. Level 3 dry eye 
disease (DED) defined by Dry Eye WorkShop (DEWS) [2] is 
diffuse punctate staining with erosion or filament on 
cornea with fast tear breaking time (TBUT) of up to < 5 
seconds with severe symptoms [2]. The treatments for 
Level 3 DED recommended by DEWS 1 are autologous 
serum or umbilical cord serum, contact lenses or 
permanent punctal occlusion. These treatments 
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recommended by DEWS 1 have some setbacks; the 
autologous serum or umbilical cord serum can be 
expensive to acquire, because production of serum eye 
drops requires much time and labor [3]. Contact lens can 
be difficult for some patients to wear and tolerate. 
Treatment with permanent punctum occlusion may 
cause epiphora [4]. 
New treatment option such as using amniotic membrane 
has been increasing in popularity. However, the amniotic 
membranes are expensive and uncomfortable for 
patients [5]. Vision can be affected for daily life as shown 
in Table 1. 
 
Table 1: Comparison between Amniotic Membrane and Amniotic Fluid 
 Amniotic membrane ( Prokera, Bio-tissue, Miami, Florida, USA) [5] Amniotic fluid (FloGraft, (Applied Biologics Scottsdale, AZ USA) [6] 
Cost More expensive about $600 Less expensive about $200 
Comfort Less comfort/with big ring More comfort/fluid 
Vision Translucent (blurred)/hazy Media Transparent (clear) 
Human amnion and amniotic fluid (AF) play a significant 
role in the development and protection of the body’s 
complex physiological system [6, 7]. AF contains native 
nutrients and growth factors including hormones such as 
Transforming Growth Factors Beta1 (TGFß1), Endothelial 
Growth Factors (EGF), and Fibroblast Growth Factors 
(FGF). The composition of AF changes as the gestation 
progresses. Hamid et al. reported isolation of pluripotent 
stem cells from full-term AF [8]. It has been 
demonstrated in peer-reviewed journals that the natural 
biologic properties of the placenta have been shown to 
promote tissue repair and management of localized 
inflammation [9-11]. While AF may be less expensive and 
comfortable to apply, it has the ability for a long term 
combined therapy with amniotic membranes or 
traditional therapy for DED. Therefore, AF may be a good 
alternative and is worthwhile to investigate further. 
Hence, the aim of this study was to assess whether AF 
either mixed with artificial tears or soaked with a soft 
contact lens (SCL) as a treatment for severe DED would 
improve its signs and or symptoms. 
METHODS 
This is a retrospective pilot study of 22 eyes of 11 
subjects in Dr. Chen’s clinic in Honolulu, Hawaii, the 
United States in 2017 (from January 2017 to December 
2017). This study was approved by the Institutional 
Review Board (IRB) of the University of Hawaii. All 
patients signed written informed consents for the 
treatment. The study was performed in accordance with 
the Declaration of Helsinki and other applicable 
guidelines and regulations. Ethical approval has been 
received accordingly. Sterile SCL Acuvue Oasys of Plano 
with 8.8 base curve and 14 mm diameters by Johnson 
and Johnson were used to soak in FloGraft, which is an 
AF 30 minutes before placing in 12 eyes in group 1 and 
treated for one week. Soft contact lenses were soaked 
with 0.25 mL FloGraft for one hour. In Group 2, 10 eyes 
were treated with 6 mL of sterile artificial tears mixed 
with 0.25 mL of FloGraft four times a day for one week. 
All eyes had level 3-4 dry disease classified by DEWS 1 
with diffuse Superficial Punctate Keratitis (SPK) and fast 
Tear Breaking up Time (TBUT) (<5 second) with severe 
symptoms (Level 3-4).  Photos were taken with 
fluorescein stain on cornea before the treatment, and 
one week after it, to compare distribution of punctate 
staining. Questions were asked for the symptom of DED 
adopted from Ocular Surface Disease Index (OSDI) 
questionnaires before and after the treatment [12]. 
“FloGraft® is an AF regulated under Section 361 of the 
Public Health Status Act and meets the criteria of Title 21 
Code for Federal Regulation (CFR) 1271.3 and 1271.10” 
Applied Biologics (Applied Biologics Scottsdale, AZ USA). 
Outcome measures of this study were improvement of 
symptoms or signs or both after one week at a follow-up 
examination. Patients subjectively had one or more less 
complaints of the following symptoms such as blurring of 
vision, pain, dryness, itching, red eye or mucus discharge, 
which were asked and recorded. These answers were 
considered as the symptom improvement.  
Ocular Surface Disease Index questionnaires scores were 
not completed because some elderly non-English 
speaking patients in this study had difficulties to 
complete the questionnaire. Less distribution of punctate 
staining and slower TBUT compared to that before the 
treatment on cornea were identified and documented by 
photo as the sign of improvement. Data collected and 
descriptive analysis used to present frequency and 
percentages of findings in each group. 
RESULTS 
Overall 22 eyes of 11 Asian subjects with mean ± 
standard deviation (SD) age of 70±3.21 years including 2 
males (18%) and 9 (82%) females were evaluated in this 
study. Status of dry eye signs and symptom before and 
after the treatment with AF (FloGraft) soaked SCL in 
Group 1 and AF (FloGraft) with artificial tears in Group 2 
is shown in detail in Table 2. As shown in Table 2, in 
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Group 1, diffuse corneal staining improved in 5 eyes 
(42%) and in Group 2 in 5 eyes (50%). In both Groups, 
TBUT, pain, red eye, dry feeling, blurring of vision, 
secondary tearing, itchiness, and mucus discharge 
improved in 50% of eyes which means in 6 eyes in 
Group1 and 5 eyes in Group2. Taken as a whole, in Group 
1, 46% had improvement in signs or symptoms of DED 
after one week and in Group 2, 50% had improvement 
after one week. None of the cases had infection, reaction 
or inflammation needed to be treated with antibiotics or 
steroid. 
DISCUSSION 
In the current study after one week of treatment, the AF 
with SCL had 46% improvement and the AF with artificial 
tears had 50% improvement.  
Dry eye disease is a complex and multifactorial eye 
disease. It is very difficult to treat in level 3-4 as various 
treatments have been provided without sufficient 
effectiveness. There is a recent review of amniotic 
membranes extracts (AME) and amniotic extract eye 
drops (AMEED) in treating severe superficial cornea eye 
disease by Murri [13]. The review showed benefits of 
AMEED in treating superficial cornea disease. The two 
complete clinical trials on AMEED demonstrated reduced 
cornea staining, reduced inflammation, reduced pain and 
acceleration of corneal epithelium healing. However, 
there was no study on AF. The two completed clinical 
trials on AMEED were reported on ClinicalTrials.gov. The 
first is “Utilization of Amniotic Membrane Extract Eye 
Drop (AMEED) on Human Corneal Healing” and the other 
is “The Improvement of Limbal Stem Cell Deficiency 
(LSCD) in Unilateral Stem Cell Damage by AMEED.” Both 
studies were from Labafi Nejad Eye Research Center in 
Tehran, Iran [14, 15]. Another recently published paper 
by Shayan et al. indicated that AMEED increases Limbal 
stem cell (LSC) proliferation and accelerates corneal 
epithelium healing without adverse effects. It could be 
used in LSC expansion therapy [16]. The report of using 
AMEED had no adverse effects and the recommendation 
of using for LSC expansion therapy in this study is in 
accordance with our investigation. Comparing to the 
AMEED study, AF study also demonstrated increasing LSC 
proliferation and accelerating corneal epithelium healing 
without adverse effects. 
 
Table 2: Dry Eye Signs and Symptom Before and After the Treatment With Amniotic Fluid in the Two Study Groups 
Time of Assessment Evaluated Sign or Symptom 
 
Corneal 
staining 
TBUT Pain Red eye Dry feeling BOV 
Secondary 
tearing 
Itchiness 
Mucus 
discharge 
 n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
 Group 1 
Before treatment 
Diffuse,12 
eyes (100%) 
< 5 S,12 
eyes 
(100%) 
Severe 12 
eyes 
(100%) 
Severe, 12 
eyes 
(100%) 
Severe, 12 
eyes 
(100%) 
Yes, 12 eyes 
(100%) 
Severe, 12 
eyes (100%) 
Severe, 12 
eyes (100%) 
Severe, 12 
eyes (100%) 
After Treatment with 
improvement 
Localize, 5 
eyes (42%) 
>5 S, 6 
eyes 
(50%) 
Mild,  6 
eyes (50%) 
None, 6 
eyes (50%) 
None 6 
eyes (50%) 
Improve,  6 
eyes (50%) 
None, 6 eyes 
(50%) 
None, 6 
eyes (50%) 
None, 6 eyes 
(50%) 
 Group 2 
Before treatment 
Diffuse, 10 
eyes (100%) 
< 5 S, 10 
eyes 
(100%) 
Severe, 10 
eyes 
(100%) 
Severe, 10 
eyes 
(100%) 
Severe, 10 
eyes 
(100%) 
Yes, 10 eyes 
(100%) 
Severe, 10 
eyes (100%) 
Severe, 10 
eyes (100%) 
Severe, 10 
eyes (100%) 
After treatment with 
improvement 
Localize, 5 
eyes (50%) 
>5 S, 5 
eyes 
(50%) 
Mild, 5 
eyes (50%) 
None, 5 
eyes (50%) 
None, 5 
eyes (50%) 
Improve, 5 
eyes (50%) 
None, 5 eyes 
(50%) 
None, 5 
eyes (50%) 
None, 5 eyes 
(50%) 
Group 1: Used Soft Contact Lens soaked in Amniotic Fluid (FloGraft).  
Group 2: Used 6 mL of artificial tears mixed with 0.25 mL of Amniotic Fluid (FloGraft).  
TBUT: Tear break up time; BOV: Blurring of Vision; n: number; %: percentage, S: second.  
 
We believe this is the first study using AF to treat severe 
DED. Artificial tears alone cannot provide sufficient 
treatment for this level of DED [2]. Soft contact lens 
alone may provide some improvement for some cases; 
however, it may not be sufficient for some others. The 
study using cryopreserved amniotic membrane 
(PROKERA) presented by McDonald et al. demonstrated 
88% improvement of ocular surface and reduction of the 
DEWS score at one week [17]. However, it is very costly, 
uncomfortable and affect vision during the treatment 
(Table 1). This case series demonstrated the safety and 
some added effectiveness in treating severe DED with AF 
(FloGraft) combined with artificial tears or SCL in short 
term without the concern of excessive cost, 
uncomfortableness and poor vision. This study is limited 
by a small population in a single center with non-
significant difference outcomes between the two 
treatment arms.  However, both groups were treated 
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with AF with improvement in symptoms and signs. The 
strength is no adverse effects in this study for the AF. 
Future long-term multicenter large population 
prospective control studies are needed to validate the 
efficacy.  
CONCLUSIONS 
Amniotic fluid (FloGraft) may be safe to mix with artificial 
tears or soaked with SCL to treat severe DED based on 
findings of this study. It improved short term symptoms 
and signs of severe DED in this case series by about 50% 
without adverse effects. 
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